ANGO News and Press, AngioDynamics Inc. From 09/09/19

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company has been awarded a dual-source group purchasing agreement by Premier, Inc. to supply implan...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of fiscal year 2020 before the market open on Th...

The following slide deck was published by AngioDynamics, Inc. in conjunction with this Read more ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the appointment of Karen Licitra to its board of directors as a Class III director, effective July 17, 2019....

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the 39 th Annual Canaccord Genuity...

AngioDynamics ( ANGO ) has been a crappy stock over the long term, with a 10-year annualized return of only a bit more than 5% and a 15-year annualized return that is even worse. Over that same period, Medtronic ( MDT ) would have earned you about 12%/year, Becton, Dickinson ( BDX ) 15%,...

AngioDynamics, Inc. (ANGO) Q4 2019 Earnings Conference Call July 10, 2019, 08:00 AM ET Company Participants Jim Clemmer - President & CEO Michael Greiner - EVP & CFO Stephen Trowbridge - SVP & General Counsel Conference Call Participants Jason Mills - Canaccord ...

The following slide deck was published by AngioDynamics, Inc. in conjunction with their 2019 Q4 earnings Read more ...

AngioDynamics ( ANGO ) Q4 results : Revenues: $96.3M (+9.1%). More news on: AngioDynamics, Inc., Read more ...

AngioDynamics (NASDAQ: ANGO ): Q4 Non-GAAP EPS of $0.25 misses by $0.01 ; GAAP EPS of $1.54 beats by $1.41 . More news on: AngioDynamics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...